Next Generation News and Research

RSS

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the COMPLIANCE trial, a long-term study to compare external event recorders with implantable monitors in patients who have been prescribed catheter ablation therapy for atrial fibrillation (AF) at risk of post-procedure AF recurrence.

23 Sep 2009

Steelbox to showcase Video Framework software at ASIS INTERNATIONAL 2009

ASIS INTERNATIONAL 2009 -- Booth No. 4369 - Steelbox, developers of IP media appliances that deliver comprehensive switching, distribution and recording of video and audio, will showcase the integration of its products with SRI International's (SRI) Integrated Video Environment (IVE) and Aware(TM) Mobile Network, and with Telindus Surveillance Solutions Ltd's (TSS) new CIRIS Command & Control Application.

22 Sep 2009

Senate President, Massachusetts Life Sciences Center, and HHMI join for groundbreaking ceremony

Senate President Therese Murray, the Massachusetts Life Sciences Center, the Howard Hughes Medical Institute (HHMI), and key state officials gathered at the Marine Biological Laboratory (MBL) today to break ground on a $25 million renovation of the MBL's central research training facility, the Loeb Laboratory.

22 Sep 2009

Next Generation Waters wins "Best New Functional Drink" award

In a category that seems to be expanding by the second, Next Generation Waters is pleased to announce that it has won "Best New Functional Drink" at the 2009 Beverage Innovation Awards, the academy awards of the Beverage Industry. NGW beat out 38 other competitors from 12 different countries including PepsiCo's Lipton Linea, Gatorade's No Artificials, and SoBe's Pure Rush to name a few.

22 Sep 2009

Technique to reduce stroke in cardiac surgery patients

Sequoia Hospital announced today that they are one of only two hospital participant abstracts selected for oral presentation at the Society of Thoracic Surgeons Advances in Outcomes and Quality national conference held this week in San Diego, California. "Separated Cerebral and Corporeal Perfusion Reduces Stroke Risk in Cardiac Surgery Patients with Mobile Aortic Atheromata" will be presented by Audrey Fisher, MPH, Sequoia Hospital Manager of Cardiovascular Quality & Outcomes. This new technique was developed to reduce strokes in cardiac surgery patients by isolating blood flow to the brain during cardiopulmonary bypass.

22 Sep 2009

Memorial Medical Center deploys Motorola's 802.11n WLAN solution to improve patient care

The Enterprise Mobility Solutions business of Motorola, Inc. (NYSE: MOT), today announced that Lowry Computer, a leading systems integrator and Motorola channel partner, has deployed its 802.11n wireless LAN (WLAN) solution at Memorial Medical Center (MMC) of Western Michigan, a community hospital located in Ludington, Mich.

21 Sep 2009

Columbia University Medical Center performs the 100th ATS 3f Aortic Bioprosthesis implant

ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that Columbia University Medical Center has achieved 100 implants of the ATS 3f(R) Aortic Bioprosthesis. Based on the precept that 'Form Follows Function,' the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve.

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

JDSU announces key advancements in complete portfolio of tunable solutions

JDSU (NASDAQ: JDSU) (TSX: JDU) today announced key advancements as part of its strategy to offer a complete portfolio of tunable solutions in multiple form factors for use within DWDM networks.

21 Sep 2009

Invatec launches a 3-dimensional distal Embolic Protection System for Carotid Artery Stenting

Invatec, a comprehensive innovator of interventional products, today introduced FiberNet®, a 3-dimensional distal Embolic Protection System (EPS) for Carotid Artery Stenting with the lowest crossing profile (0.031’’) and highest performance capabilities on the market, manufactured by Lumen Biomedical. FiberNet provides superior deliverability and can be used in vessels ranging from 3.5 to 7 mm.

21 Sep 2009

CEO of New Mexico Software provides update on its business activities

New Mexico Software, Inc. (OTCBB: NMXC), a leading services provider of next-generation business and medical services, issued this letter today to shareholders and stakeholders of New Mexico Software to provide an update on significant business activities at the Company:

19 Sep 2009

Multiple Myeloma Research Foundation focuses on effective cancer treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that American figure skating legend and Olympic gold medalist Scott Hamilton will serve as Master of Ceremonies at the 13th Annual MMRF Fall Gala, on Saturday, Oct. 24, 2009, at the Hyatt Regency in Greenwich, Conn.

19 Sep 2009

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets in multiple therapeutic areas. The alliance will capitalize on Ambrx's recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates.

19 Sep 2009

Patient enrollment for PLATINUM workhorse trial completed by Boston Scientific

Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical program. PLATINUM is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum chromium PROMUS((R)) Element(TM) Everolimus-Eluting Coronary Stent System.

19 Sep 2009

Artificial vision enhancers to reach the market by 2011

Visually impaired or blind patients with degenerative retina conditions would be very happy if they were able to regain mobility, find their way around, be able to lead an independent life and to recognize faces and read again. These wishes were documented by a survey conducted by a research team ten years ago to find out what patients' expectations of electronic retina prostheses (retina implants) were.

19 Sep 2009

Raindance Technologies and CLC to develop software for resequencing analysis

RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next generation DNA sequencing platforms.

18 Sep 2009

SEQUENOM's first laboratory developed cystic fibrosis test launched

SEQUENOM, Inc. today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched.

18 Sep 2009

Pharmabcine raises funds to develop therapeutic antibodies in the area of cancer and inflammation

PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

Speaker Pelosi remarks on benefits for children in health insurance reform

Speaker Nancy Pelosi delivered remarks at an event for the Children's Health Fund this afternoon on the West Front Lawn of the Capitol to raise awareness for the more than 21 million children who will benefit from health insurance reform.

17 Sep 2009